Litigation

Celgene Corporation v. USV Private Limited

active

2:25-cv-06320

Auto-generating section 1 of 4: Case overview & background…

Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.

Court: U.S. District Court for the District of New Jersey

Patents at issue (3)

Plaintiffs (1)

π Celgene Corporation

Defendants (1)

Δ USV Private Limited

Summary

Celgene's 2025 pomalidomide ANDA infringement suit against USV Private Limited; listed as remaining open.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Record id: 9993467-2-25-cv-06320 · edit in Admin

Further reading

Cost of Inter Partes Review (IPR): a 2026 breakdown
An IPR ends most cases when the prior art is real. The all-in cost is roughly a tenth of full litigation — but only if you stage it right.
The patent litigation lifecycle
Most patent cases never reach trial. A defendant who understands the lifecycle makes better decisions about when to fight, when to settle, and when to invest in IPR — instead of overspending on whatever phase they happen to be in.
Lumen View v. FindTheBest (2013-2016): when a defendant fought back, the troll paid
Same patent. Same plaintiff playbook. Different outcome — because the defendant had the resources and the will to fight. Most don't. That's the asymmetry this site is built to fix.
How patent trolls operate (and why the business model works)
A junk patent generates settlement income exactly the same way as a strong one, because nobody pays $1M to test a $200k demand. The mechanics matter because the failure modes — what makes assertion campaigns expensive or risky for the troll — are exactly where defendants find leverage.
Patent law glossary
Sixty-plus patent-law terms, defined in one or two sentences each, with a link to the deeper article. The universal landing pad when an article uses a term you don't know.

All resources →